title: Persistence of cefotetan on red blood cells.
abstract: BACKGROUND
  Cefotetan can cause severe immune hemolytic anemia that may persist long after the drug is discontinued. To study the binding of cefotetan to RBCs, patients who received cefotetan were followed and tested for the presence of antibody to cefotetan.
  
  
  METHODS
  Patients receiving cefotetan were identified from pharmacy and nursing records. Blood samples obtained for routine hematology tests were analyzed. Cefotetan binding to patients' RBCs was tested using a previously characterized high-titer anticefotetan serum by gel technique. To determine the minimum amount of drug necessary for binding to occur, RBCs were incubated with serial dilutions of cefotetan at pH 7.4.
  
  
  RESULTS
  Sixty patients receiving 1 to 25 g i.v. (median, 2 g) of cefotetan were followed for 1 to 123 days (median, 18 days). All were initially positive, for cefotetan on RBCs. Positivity persisted for up to 98 days after the last dose of drug. Fifteen patients became negative during follow-up. The first negative sample occurred at Day 30 to 123. Using the midpoint between the last positive and first negative to estimate of the duration of positivity, we estimate that cefotetan remains RBC-bound for 16.5 to 92 days (median, 67.5 days). During the follow-up period, five patients developed anticefotetan detectable in the serum. Twenty patients receiving other cephalosporin antibiotics showed no specific reactivity of their RBCs with anticefotetan. In vitro studies showed a minimum necessary drug concentration of 1 micromol/L at physiologic pH, which was not significantly altered by RBC pretreatment with ficin, sialydase, or DTT.
  
  
  CONCLUSIONS
  Cefotetan is tightly bound to RBCs after intravenous administration and remains detectable for weeks after the last dose. Antibodies to cefotetan may occur in about 8 percent of patients receiving the drug. The minimum necessary concentration for RBC binding is low compared to an estimated plasma concentration of 240 micromol/L from a single i.v. dose of 1 g.
authors.affiliation: University of Michigan Medical School, Ann Arbor, Michigan 48109-0054, USA. rddvnprt@umich.edu
authors.forename: Robertson D
authors.initials: RD
authors.lastname: Davenport
authors.forename: W John
authors.initials: WJ
authors.lastname: Judd
authors.forename: Louann R
authors.initials: LR
authors.lastname: Dake
mesh_terms: D000744:Anemia, Hemolytic, Autoimmune / Q000139:chemically induced*; D000918:Antibody Specificity; D001803:Blood Transfusion; D015313:Cefotetan / Q000009:adverse effects* / Q000097:blood / Q000276:immunology; D002511:Cephalosporins / Q000276:immunology; D003429:Cross Reactions; D004229:Dithiothreitol / Q000494:pharmacology; D004306:Dose-Response Relationship, Immunologic; D004910:Erythrocyte Membrane / Q000737:chemistry / Q000187:drug effects*; D005361:Ficain / Q000494:pharmacology; D005500:Follow-Up Studies; D006801:Humans; D013997:Time Factors
chemical_list: D002511:Cephalosporins; D015313:Cefotetan; D005361:Ficain; D004229:Dithiothreitol